© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Lilly's Donanemab Approved by FDA for Treatment of Early Symptomatic AD
July 02, 2024
Donanemab, now 1 of 2 antiamyloid medications available, is unique based on evidence that it can be used in limited duration treatment, based on removal of plaque.
First Consensus Guidance Published on Monitoring Early-Stage Type 1 Diabetes
July 02, 2024
The international statement targets primary care clinicians and endocrinologists with detailed guidance on monitoring disease progression and providing education.
UPDATE: ACIP Vote Unanimous to Recommend Merck 21-Valent Pneumococcal Shot for Older Adults
July 01, 2024
The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.
FDA Accepts 2 NDAs, Grants Priority Review for Crinecerfont for Pediatric, Adult CAH
July 01, 2024
Neurocrine Biosciences made the announcement and said, if approved in December, crinecerfont will be the first new treatment and treatment approach to CAH in 70 years.
Management of Congenital Adrenal Hyperplasia in Adults: Challenges with Standard of Care
July 01, 2024
The standard of care for congenital adrenal hyperplasia has not changed in more than 60 years nor have the challenges it presents been overcome.
Emerging Therapies in Management of Congenital Adrenal Hyperplasia
July 01, 2024
Investigational treatments for congenital adrenal hyperplasia are focused on new ways to manage symptoms without the need for supraphysiologic doses of glucocorticoids.
Androgen Management in Congenital Adrenal Hyperplasia: A Primer
July 01, 2024
Current therapies fall short of quelling the long-term exposure to and adverse effects of excessive androgen levels experienced by adults with CAH.
ACIP Revises Recommendation for Adult RSV Vaccination
June 27, 2024
The committee endorsed a universal recommendation for a single lifetime dose of RSV vaccine for adults aged ≥75 years and a risk-based recommendation for those aged 60 to 74 years.
Older US Adults Without CVD Still Using Aspirin for Primary Prevention
June 26, 2024
Nearly one-third of US adults aged 60 years and older continue to take daily aspirin despite published evidence recommending against use in the absence of CVD.
CGM Data May Enhance Prediction of Risk for Type 1 Diabetes in Those with Early Stage Disease
June 24, 2024
ADA 2024. The risk of progression to stage 3 type 1 diabetes may be better predicted using a combination of patient and CGM data, a new study suggests.